ZHONGHUA YANGSHENG BAOJIAN ›› 2023, Vol. 41 ›› Issue (16): 18-21.

Previous Articles     Next Articles

Inhibition of NSCLC by Combination of Breviscapine and Tetramethylpyrazine and its Mechanism

SHI Li-ping1, LIU Di-lin2, LYU Gen-mei2   

  1. 1. Department of Pharmocology, Gannan Health Vocational College, Ganzhou Jiangxi, 341000, China;
    2. Department of Pharmocology, Ganzhou Cancer Hospital, Ganzhou Jiangxi, 341000, China
  • Online:2023-08-16 Published:2023-08-08

Abstract: Objective To investigate the mechanism of inhibition of NSCLC by combination of Breviscapine and Tetramethylpyrazine. Methods Non-small cell lung cancer A549 cells were divided into control group, Breviscapine group, Tetramethylpyrazine group,Breviscapine and Tetramethylpyrazine group. Detect cell survival rate by MTT, apoptosis by flow cytometry, cell migration ability by Transwell test. Related pathway changes were detected by Western Blot. Results The cell survival rate of A549 cells in the control group, Breviscapine group, Tetramethylpyrazine group, and Breviscapine and Tetramethylpyrazine group decreased after 24h (P<0.05). Compared with control group, A549 cells showed significant apoptosis and cells in Breviscapine and Tetramethylpyrazine group showed the most evident changes; Transwell showed that the number of trans-membranous cells decreased significantly compared with the control group and membrane penetration was most evidently inhibited in combination group. Western blot showed that the expression of p-JAK2 and p-STAT3 decreased after drug administration, and the two proteins were lowest in the Breviscapine and Tetramethylpyrazine group. Conclusion Breviscapine combined with Tetramethylpyrazine inhibited the proliferation, migration and invasion of the non-small cell lung cancer cell line A549, and the mechanism may be related to the inhibition of the JAK-STAT pathway.

Key words: Breviscapine, Tetramethylpyrazine, non-small cell lung cancer

CLC Number: